Altimmune is trading 5.26% higher at $3.40, with no clear company-specific catalyst identified.
- The latest official announcement, dated September 3, concerned management’s planned participation in the Wells Fargo 21st Annual Healthcare Conference on September 10; it did not state a related share-price reaction.
- The broader market was modestly lower while Altimmune moved higher, leaving the reason for today’s advance unclear.